drugset / Trial / NCT00010322

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00010322

Phase 3 Terminated Intarcia Therapeutics
Treatment

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Toremifene may fight breast cancer by blocking the uptake of estrogen by the tumor cells. Atamestane may fight breast cancer by blocking the production of estrogen. It is not yet known if toremifene is more effective with or without atamestane. PURPOSE: Randomized phase III trial to compare the effectiveness of toremifene with or without atamestane in treating postmenopausal women who have metastatic breast cancer.

Timeline

Start
2000-10
Primary completion
2001-05
Completion
2001-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Atamestane Small molecule Oral
Subject Toremifene Small molecule Oral

Indications